Tectonic recently announced its third-quarter 2024 financial results, highlighting signif Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback